Réglementation et droit · 26/09/20021 min de lecture
Prospective Grant of Exclusive License: Drug and Method for the Therapeutic Treatment of Head and Neck Cancer
Traduction automatique locale · Langue originale de la source
Résumé
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. provisional patent application 06/911,227 (DHHS ref. no. E-385-86/0) filed September 24, 1986 and issued on January 01, 1990 as USPSN 4,892,827 (no foreign rights available from DHHS) and entitled "Recombinant pseudomonas exotoxins: Construction of an active immunotoxin with low side effects," U.S. patent application 07/341,361 (DHHS ref. no. E-135-89/0) filed April 21, 1989 and entitled "Recombinant antibody--Toxin fusion protein," now abandoned in favor of USPASN 07/865,722, U.S. patent application 07/865,722 (DHHS ref. no. E-135-89/1), a file-wrapper-continuation of USPASN 07/341,361, filed April 08, 1992 and issued as USPSN 6,051,405 on April 18, 2000 and entitled, "Constructs encoding recombinant antibody-toxin fusion proteins," U.S. patent application 08/461,825 (DHHS ref. no. E-135-89/ 2), a divisional of 07/865,722, filed June 05, 1995 and issued as USPSN 5,863,745 on January 26, 1999 and entitled, "Recombinant antibody-